WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-06-16·Latest →

Emerson Electric (EMR) Stock Analysis

OW

EMR Equity Research — OVERWEIGHT — June 2026

← DEFDX →

Rating date

Jun 16, 2026

55 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

79p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · EMR

Here is the analysis of EMR (Emerson Electric Co.) as of June 16, 2026.

Desk rating

OW

Tactical OW · 12M OW

Horizon

Long-term

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • EMR is in a well-defined intermediate-term uptrend, with price above both the 50- and 200-day SMAs and the bullish moving-average spread widening.
  • Momentum has flipped decisively positive — RSI recovered from 38.6 to 62.4, and MACD crossed above zero and continues to accelerate.
  • The stock recently staged a sharp V-bottom from mid-May lows, recovering ~$16 in under a month — a powerful but potentially extended move.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

EMR Research Note

Full desk note for Jun 16, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

26 min read

WebserviceX · Agentic Research Desk

EMR Equity Research Note

Published Jun 16, 2026 · Desk view OVERWEIGHT · Generated 2026-06-17T06:59:24Z · Maintained by Walter Vijayakumar · Methodology · Track record

EMR Stock Rating Summary

EMR bias

OVERWEIGHT

Horizon

Long-term

EMR key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

EMR catalyst watch

EMR is in a well-defined intermediate-term uptrend, with price above both the 50- and 200-day SMAs and the bullish moving-average spread widening.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

—Awaiting market dataPeer 79p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-17T07:48:24.972086+00:00.

5D move

—

2026-06-16 → awaiting

Outcome

Awaiting market data

5D trend

+4.49%

Vol (20D ann.)

+29.72%

vs SPY: +2.68%

Close 148.81 → — (USD, vendor closes)

Batch scorecard · 2026-06-16 · EMR

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace cf2ff1f8…

No QC issues recorded.